NCT00427921View on ClinicalTrials.gov

Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS)

PHASE3CompletedINTERVENTIONAL
Enrollment

304

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions
Crohn's Disease
Interventions
BIOLOGICAL

adalimumab

160 mg loading dose, 80 mg at week 2, 40 mg every other week

Trial Locations (1)

60064

Global Medical Information - Abbott, Abbott Park

Sponsors

Lead Sponsor

Abbott
All Listed Sponsors
lead

Abbott

INDUSTRY

NCT00427921 - Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS) | Biotech Hunter | Biotech Hunter